Cutaneous leishmaniasis: current and future management.
Leishmaniasis remains a major world health problem that continues to increase in incidence. This review considers epidemiology, clinical features, diagnosis and current treatment options. Recent developments in the treatment of simple cutaneous leishmaniasis are discussed followed by speculation about future therapies.
Hepburn
Neill C
NC
Lincoln County Hospital, Lincoln, LN2 5QY, UK. Neill.Hepburn@ULH.NHS.UK
D000666:Amphotericin B / Q000627:therapeutic use; D000818:Animals; D000967:Antimony Sodium Gluconate / Q000627:therapeutic use; D006801:Humans; D007167:Immunotherapy; D007891:Leishmania / Q000502:physiology; D016773:Leishmaniasis, Cutaneous / Q000175:diagnosis / Q000188:drug therapy*; D010303:Paromomycin / Q000627:therapeutic use; D010767:Phosphorylcholine / Q000031:analogs & derivatives* / Q000627:therapeutic use
D010767:Phosphorylcholine; C039128:miltefosine; D010303:Paromomycin; D000666:Amphotericin B; D000967:Antimony Sodium Gluconate